In short
Clinical trials of IG-TREGS are studying an adoptive immunotherapy approach in adults after matched sibling donor stem cell transplant. The main goals are to check safety, tolerability, and the best dose for preventing graft-versus-host disease (GvHD), a serious transplant complication.
Key points
- IG-TREGS is being studied in a Phase 1 clinical trial in adults who receive stem cell transplants from a fully matched sibling donor. The trial is looking at whether the treatment can help prevent graft-versus-host disease, or GvHD. The main goals are to measure safety, tolerability, and the maximum tolerated dose. Researchers are also tracking infusion toxicity, other side effects, and dose-limiting toxicities during the first 90 days after infusion. The trial is authorised and plans to enroll 26 patients.
Trial overview
This article covers one authorised clinical trial of IG-TREGS, also described in the source as inducible HLA-G+ regulatory T cells or iG-Tregs. The study is testing IG-TREGS as an adoptive immunotherapy, which means immune cells are given as a treatment, in adults after allogeneic hematopoietic cell transplantation from a fully matched sibling donor.
The main goal is to study prevention of graft-versus-host disease (GvHD), a transplant complication where donor immune cells can attack the patient’s body. The brief summary also says the study aims to evaluate safety after allo-HCT to prevent acute GvHD, often shortened to aGvHD.
Who can participate
The trial is designed for adult patients undergoing hematopoietic stem cell transplantation from a fully compatible donor sibling. This means the donor is a brother or sister whose tissue type matches the patient’s well enough for transplant.
The source data do not list other participant groups, so the trial focus is narrow and specific to this transplant setting.
What is being measured
The main outcome is to define the safety, tolerability, and maximum tolerable dose (MTD) of IG-TREGS for GvHD prevention. Safety means whether the treatment causes harmful effects, while tolerability means how well patients can handle it.
Researchers will measure infusion toxicity within 1 hour after the infusion and grade it using CTCAE version 4, which is a standard side-effect scoring system used in trials. They will also track any other toxicities related to the infusion, including worsening of GvHD, infections, and disease relapse.
Another key part of the study is dose-limiting toxicities (DLTs), which are serious side effects that help researchers decide whether a dose is too high. During the dose-escalation phase, a dose is considered safe if a DLT happens in only 1 of 6 patients, or in 0 of 3 patients in a cohort.
The study also follows adverse effects during the first 3 weeks after IG-TREGS infusion, and the full safety window runs until 90 days after infusion. This time frame helps researchers see both early and later problems after treatment.
Trial phase and status
This study is a Phase 1 trial. Phase 1 studies usually focus on safety, side effects, and dose finding rather than proving that a treatment works in a large group.
The trial status is Authorised, and the planned enrollment is 26 participants. The study type is interventional, which means the researchers are actively giving a treatment and measuring what happens.
Key medical terms
Allogeneic transplant means the stem cells come from another person, not from the patient. In this trial, the donor is a sibling who is fully compatible.
Acute GvHD is a form of graft-versus-host disease that can happen soon after transplant. The trial brief summary specifically mentions prevention of aGvHD.
CTCAE is a standard way to grade side effects in clinical trials, so researchers can compare how serious they are. Cohort means a small group of patients studied together at one dose level.
Dose escalation means the dose is increased step by step in different groups to find the safest dose range. This is why the study can identify the maximum tolerated dose.